Clinical

Dataset Information

0

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors


ABSTRACT: The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of livmoniplimab alone and in combination with budigalimab. The study will consist of 2 parts: dose escalation and dose expansion.

DISEASE(S): Colorectal Cancer,Locally Advanced Or Metastatic Solid Tumors,Solid Tumors,Neoplasms,Cancer,Advanced Solid Tumors Cancer

PROVIDER: 2295725 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2243822 | ecrin-mdr-crc
2021-09-02 | GSE182994 | GEO
2023-12-15 | GSE249023 | GEO
2023-12-15 | GSE249542 | GEO
2017-03-07 | GSE89934 | GEO
2021-01-31 | GSE144326 | GEO
2017-03-07 | GSE89933 | GEO
| 2235325 | ecrin-mdr-crc
2017-03-07 | GSE89935 | GEO
| 2238930 | ecrin-mdr-crc